Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator
Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator
复制标题
DOI：
10.3892/ol.2017.6658
复制
发表时间：
2017-10-01
期刊：
影响因子：
2.9
通讯作者：
Kikkawa, Fumitaka
中科院分区：
文献类型：
--
作者：
Sakata, Jun;Kajiyama, Hiroaki;Kikkawa, Fumitaka
已有研究表明，锌指蛋白E-box结合同源框1（ZEB 1）在恶性实体瘤中的表达对患者的临床预后具有重要意义。然而，上皮性卵巢癌（EOC）患者中ZEB 1表达与生存率之间的关系尚不清楚。本研究的目的是使用免疫组化染色检测上皮性卵巢癌中ZEB 1表达的程度，并研究其与患者预后的关系。共有40例EOC患者最初接受细胞减灭术和系统化疗。根据染色面积的大小和强度，将ZEB 1表达化学分类为阴性、弱、中等和强。随后，研究了ZEB 1表达与复发/无进展生存（RFS）率之间的关系。本研究中患者的中位年龄为54岁（范围：22-72岁）。在这些患者中，15例（37.5%）表现为国际妇产科联盟I期疾病，10例（25.0%）、13例（32.5%）和2例（5%）分别为II、III和IV期疾病。ZEB 1阴性表达的患者无复发。此外，与阴性表达相比，ZEB 1表达被确定为较差RFS率的显著预测因子（阴性与弱、中等和强，P=0.0126）。此外，多变量分析显示，中等和强ZEB 1表达水平是EOC患者RFS率较差的重要预后指标（风险比，2.265; 95%置信区间，1.072-8.021; P=0.0349）。限制分析透明细胞/粘液组织学类型的患者，中等/强ZEB 1表达的患者表现出明显较差的RFS率（P=0.0025）。ZEB 1阳性表达可能是预测EOC患者RFS不良的指标。
Several previous studies have revealed that the expression of zinc finger E-box binding homeobox 1 (ZEB1) in solid malignancies has an important significance on the clinical outcome of patients. However, the association between ZEB1 expression and survival in patients with epithelial ovarian carcinoma (EOC) remains unclear. The objective of the present study was to examine the extent of ZEB1 expression in EOC using immunohistochemical staining and investigate its association with patient outcome. A total of 40 patients with EOC initially treated with cytoreductive surgery and systematic chemotherapy were enrolled. ZEB1 expression was immunohistochemically categorized as negative, weak, moderate and strong according to the size of the staining area, and intensity. Subsequently, the associations between ZEB1 expression and recurrence/progression-free survival (RFS) rate were examined. The median age of patients in the current study was 54 years old (range, 22-72 years old). Among these patients, 15 (37.5%) exhibited International Federation of Gynecology and Obstetrics stage I disease, and 10 (25.0%), 13 (32.5%), and 2 (5%) had stage II, III, and IV disease, respectively. No patients with negative expression of ZEB1 experienced recurrence. In addition, ZEB1 expression was identified to be a significant predictor of a poorer RFS rate compared with negative expression (negative vs. weak, moderate and strong, P=0.0126). Furthermore, multivariate analyses revealed that moderate and strong ZEB1 expression levels were significant prognostic indicators of a poorer RFS rate in patients with EOC (hazard ratio, 2.265; 95% confidence interalv, 1.072-8.021; P=0.0349). Confining analysis to patients with the clear-cell/mucinous histological type, those with moderate/strong ZEB1 expression demonstrated a significantly poorer RFS rate (P=0.0025). Positive ZEB1 expression may be an indicator to predict unfavorable RFS in patients with EOC.